Zobrazeno 1 - 10
of 55
pro vyhledávání: '"David R Luke"'
Autor:
Alain Tremblay, Ranjani Somayaji, Arthur Lau, Fatma Eser, Rahmet Guner, David R Luke, Ŏ Fehmi Tabak, Mark Hepokoski, Nancy Gardetto, Steven A Conrad, Sunil D Kumar, Kalyan Ghosh, Stephen M Robbins, Donna L Senger, Daisy Sun, Rachel K S Lim, Jonathan Liu, Ridvan Karaali, Daniel Muruve
Publikováno v:
BMJ Open, Vol 14, Iss 3 (2024)
Objective Dipeptidase-1 (DPEP-1) is a recently discovered leucocyte adhesion receptor for neutrophils and monocytes in the lungs and kidneys and serves as a potential therapeutic target to attenuate inflammation in moderate-to-severe COVID-19. We aim
Externí odkaz:
https://doaj.org/article/ce794de0f6f943398e235ef10b530862
Autor:
David R Luke, Karen Ka Yan Lee, Anne Kizy, Daisy Sun, Ronald Harris, Tyler D Luke, Conroy Cheng
Publikováno v:
Diabetes & its Complications. 5
Background/Purpose: Treatment of Type 2 diabetes (T2D) remains an unmet need, particularly a medication with low toxicity. BTI320 (SugarDown®) is fractionated galactomannan with inhibitory activity on carbohydratehydrolyzing enzymes. The primary obj
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f11cb38b483ddf863422bc945f2b71b0
https://doi.org/10.33425/2639-9326.1096
https://doi.org/10.33425/2639-9326.1096
Publikováno v:
Trends in Diabetes and Metabolism. 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f014effea328d21cb0a8cbcab86bdeec
https://doi.org/10.15761/tdm.1000116
https://doi.org/10.15761/tdm.1000116
Publikováno v:
Clinical Pharmacology in Drug Development
BTI320 is a proprietary fractionated mannan polysaccharide being studied for attenuation of postprandial glucose excursion. The apparent blood glucose‐lowering effect of this compound is effective in lowering postprandial hyperinsulinemia, particip
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ae28875b9eb24a47ab27437171979af
http://europepmc.org/articles/PMC6585810
http://europepmc.org/articles/PMC6585810
Autor:
Randall Hoover, Harry Alcorn, Susan K. Paulson, Laura Lawrence, Sue Cammarata, David R. Luke, Megan Quintas
Publikováno v:
Journal of Clinical Pharmacology
Delafloxacin, a fluoroquinolone, has activity against Gram‐positive organisms including methicillin‐resistant S aureus and fluoroquinolone‐susceptible and ‐resistant Gram‐negative organisms. The intravenous formulation of delafloxacin conta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99a99deb11ec211c54fd535cbf51d44a
http://europepmc.org/articles/PMC6718009
http://europepmc.org/articles/PMC6718009
Autor:
Thomas Marbury, David R. Luke, Susan K. Paulson, Richard A. Preston, Megan Quintas, Sue Cammarata, Randall Hoover, Laura Lawrence
Publikováno v:
The Journal of Clinical Pharmacology. 57:328-335
Delafloxacin is a novel anionic fluoroquinolone with robust activity against Gram-positive, Gram-negative, atypical, and anaerobic bacteria, including methicillin-resistant S aureus. Delafloxacin is currently being studied for the treatment of acute
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::27912ca9aab5c4c452b898719ba526a7
https://doi.org/10.1002/jcph.817
https://doi.org/10.1002/jcph.817
Autor:
Magee Thomas Victor, Thuy-Trinh Nguyen, Joseph A. Abramite, Yue Shen, Jian Lin, Jiri Aubrecht, Fadia Dib-Hajj, Jeremy T. Starr, Alita A. Miller, Matthew Frank Brown, Shawn H. MacVane, Michael D. Huband, Li Zhang, Karl Granskog, Bryan Li, Jinshan Michael Chen, James M. McKim, John P. O'Donnell, Karen L. Leach, Paul C. Wilga, David P. Nicolau, Sandra P. McCurdy, Mark Edward Flanagan, Antonia F. Stepan, Andrew P. Tomaras, Mark C. Noe, Michael Kuhn, Scott B. Seibel, Rebecca Irvine, Jinfeng Xu, David C. Ackley, David R. Luke, Jared L. Crandon, Joel R. Hardink, Andrew Butler
Publikováno v:
Journal of Medicinal Chemistry. 56:5079-5093
We report novel polymyxin analogues with improved antibacterial in vitro potency against polymyxin resistant recent clinical isolates of Acinetobacter baumannii and Pseudomonas aeruginosa . In addition, a human renal cell in vitro assay (hRPTEC) was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e495f860c984ae946db4940511966812
https://doi.org/10.1021/jm400416u
https://doi.org/10.1021/jm400416u
Publikováno v:
Hospital Pharmacy. 46:427-431
Objective The aim of the study was to compare all-cause adverse events (AEs) and those caused by intravenous (IV) catheter-site complications (IVCSCs) using data from a previously published study of the use of linezolid or vancomycin for treatment of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::11da25b23f6db753061a694612aae332
https://doi.org/10.1310/hpj4606-427
https://doi.org/10.1310/hpj4606-427
Autor:
G. Ralph Corey, Andrew F. Shorr, Melinda K. Lacy, Thomas C. Hardin, David R. Luke, Steven L. Barriere, Whedy Wang, Boris Nogid, Martin E. Stryjewski
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 61
BACKGROUND When hospital-acquired or ventilator-associated bacterial pneumonia (HABP/VABP) is caused by gram-positive and gram-negative pathogens or both (mixed infections), the adequacy of gram-negative coverage (GNC) can confound the assessment of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb34aa023829dbc0015b72b55f47a283
https://pubmed.ncbi.nlm.nih.gov/26316562
https://pubmed.ncbi.nlm.nih.gov/26316562
Publikováno v:
The Journal of Clinical Pharmacology. 41:210-216
Two studies were conducted in HIV-infected subjects to assess the potential for azithromycin to interact with zidovudine and dideoxyinosine. Both studies used 12 subjects. The zidovudine study dosed subjects with 1200 mg/day of azithromycin (n = 7) (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2da78b67aed0de47fb3d7dea56f1fe6c
https://doi.org/10.1177/00912700122009908
https://doi.org/10.1177/00912700122009908